Two control groups of ER-positive carcinomas, N=22 HER2-negative (IHC score 0/
HER2-non-amplified) and N=22 HER2-positive (HER2 IHC score 3+/
HER2-amplified), were subjected to global transcriptomics by
Whole-Genome DASL assay (Illumina Inc., San Diego, CA) according to the manufacturer’s instructions (Supplementary Methods and related Supplementary Figures, Supplemental Digital Content 1,
http://links.lww.com/PAS/A652). Genes with differential expression in HER2-positive versus HER2-negative carcinomas were identified on the basis of
t test significance
P<0.01 and on mean gene expression variations >±2-fold. Cluster analysis was performed using GEDAS software and the “Fuzzy Self-organizing Maps” algorithm with cosenic distance.17 (
link)
Subsequently, these 2 cohorts and the double-equivocal carcinomas confirmed at least by 2 FISH observers were analyzed by a customized nCounter GX CodeSet assay (NanoString) including the gene signature obtained by DASL, 4 housekeeping genes, 6 positive quality controls, and 8 negative quality controls (Supplementary Methods, Supplemental Digital Content 1,
http://links.lww.com/PAS/A652). Analysis of genes significantly differentially expressed between subgroups was performed in MeV 4.8 software (version 10.2) using the
t test (critical
P-value=0.05). Unsupervised clustering was performed by
nSolver 3.0 (NanoString).
Marchiò C., Dell’Orto P., Annaratone L., Geyer F.C., Venesio T., Berrino E., Verdun di Cantogno L., Garofoli A., Rangel N., Casorzo L., dell’Aglio C., Gugliotta P., Trisolini E., Beano A., Pietribiasi F., Orlassino R., Cassoni P., Pich A., Montemurro F., Mottolese M., Vincent-Salomon A., Penault-Llorca F., Medico E., Ng C.K., Viale G, & Sapino A. (2018). The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment. The American Journal of Surgical Pathology, 42(9), 1190-1200.